Brief: Alkermes Announces Initiation Of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 For Treatment Of Narcolepsy Type 1
24/04/2024 12:45
April 24 (Reuters) - Alkermes Plc ALKS.O :
* ALKERMES ANNOUNCES INITIATION OF VIBRANCE-1 PHASE 2 STUDY
EVALUATING ALKS 2680 FOR THE TREATMENT OF NARCOLEPSY TYPE 1
Source text for Eikon: ID:nPn1bg6gVa
Further company coverage: ALKS.O
((Reuters.Briefs@thomsonreuters.com;))